Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May, Apogee Therapeutics announced positive interim results from its Phase 1b trial of APG808. APG808 is a novel and half-life extended IL-4Rα antibody being developed for the treatment of various inflammatory and immunology (I&I) conditions, such as atopic dermatitis/AD, asthma, eosinophilic esophagitis/EoE, and chronic obstructive pulmonary disease/COPD.

The Phase 1b trial was a double-blind, placebo-controlled, and multiple-dose study that evaluated the safety, tolerability, and initial efficacy of APG808 in 22 adult patients with mild-to-moderate asthma. Results from the trial showed that APG808 was well tolerated through 12 weeks of follow-up, with a safety profile consistent with other anti-IL-4Rα class drugs. No severe adverse events were reported, and no adverse events led to study discontinuation.

Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma

A scientist in a lab running tests on a variety of biopharmaceuticals.

APG808 is a novel subcutaneous monoclonal antibody targeting IL-4Rα, which is a clinically validated target across eight Type 2 allergic diseases. Preclinical studies indicated that APG808 has similar binding properties and femtomolar affinity for IL-4Rα as Dupixent and showed similar inhibition. Asthma, which is a common non-communicable disease, is estimated to affect 40 million adults and 12 million children across the US, France, Germany, Italy, Japan, Spain, and the UK.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company that develops novel biologics for the treatment of various inflammatory and immunological indications.

While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.